



Back to School webinar: Real World Risk Prediction in Learning Health Systems

September 8, 2020
2:00 – 3:00 p.m. ET



■ The audio and slide presentation will be delivered directly to your computer

- Speakers or headphones are required to hear the audio portion of the webinar.
- If you do not hear any audio now, check your computer's speaker settings and volume.
- Please take the questionnaire after watching the webinar.



Disclaimer

This webinar is brought to you by AcademyHealth through the [HSRProj program](#). HSRProj is a joint effort of AcademyHealth and the Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, funded by the National Library of Medicine, National Institutes of Health, U.S. Department of Health & Human Services.

The opinions and recommendations expressed in this presentation are those of the individual presenters, and do not necessarily reflect those of AcademyHealth or the National Library of Medicine.

Welcome!

Margo Edmunds, Ph.D.

Vice President, Evidence Generation
and Translation

AcademyHealth



Patricia Gallagher, M.L.S, M.A., AHIP

Project Officer

U.S. National Library of Medicine
(NLM)



NLM Resources for HSR



HSR General Resources

- Data, Tools and Statistics
- HSR Social Media Resources
- Grants, Funding and Fellowships
- Education and Training
- Guidelines, Journals, Other Publications
- Key Organizations
- Legislation
- Meetings, Conferences and Webinars
- State and State/Local Resources

HSR Topics

- Aging Population Issues
- Behavioral and Mental Health
- Child Health Services Research
- Community Benefits / Community Health Needs Assessment
- Comparative Effectiveness Research (CER)
- Data Literacy & Management
- Dissemination and Implementation Science
- Domestic Violence
- Evaluation Resources for Assessing HIT Systems and HIT Implementation, Adoption and Use
- Evidence-Based Practice and Health Technology Assessment
- Health Care Reform, Health Economics, and Health Policy
- Health Disparities
- Health Informatics
- Health Literacy and Communication

Small Email Search

Enter your email address in the box below for updates

Submit

About HSRIC | FAQ | Suggestions?

In the Spotlight

Current HSR News

Jul 31, 2020
The Impact of the Pandemic on Pregnancy: A Research Inquiry

Jul 31, 2020
CMS and CDC announce provider reimbursement available for counseling patients to self-monitor at home of COVID-19 testing

Jul 31, 2020
How States Are Using Comprehensive Medicaid Managed Care to Strengthen and Improve Primary Health Care

More News

<https://www.nlm.nih.gov/nichsr>

HSRProj (Health Services Research Projects in Progress)

Information about all health services research and public health projects

Enter one or more term(s) to search. Enter a multi-word term or phrase in quotes.
Examples: asthma; "long term care"

Search:

Advanced Search



HSRProj
Search Browse Latest Projects Browse Supporting Agencies
About HSRProj
FAQs Search Tips What's New Brochure Submit a Project
HSRProj Partners
AcademyHealth Sheps Center, UNC-CH
Other NLM Resources
Clinical Trials HSR Information Central HSR NICHSR PHPartners.org PubMed

Glossary



Recently Digitized



Collections



Home > NICHSR > Finding and Using Health Statistics

Introduction
About Health Statistics
Common Terms
Health Data Sources
Finding Health Statistics
Reference Materials

Finding and Using Health Statistics

About Health Statistics

How many Americans are affected by cardiovascular disease each year? Did the number of Americans with health insurance increase significantly following the passage of the Affordable Care Act? How do the leading causes of death in the United States differ from those worldwide?

The answers to these important questions and many others lie in the data collected by government, private, and non-profit agencies and organizations. The health statistics reported by these groups are integral to monitoring trends in the health status of populations, planning the allocation of health care resources, and evaluating the effectiveness of public health interventions.

This course for librarians and students in health sciences describes different types of health statistics, how they are collected, and where they can be found.

Course Goals

1. Understand what health statistics measure and how to use them to improve general health
2. Gain a basic knowledge of the statistical terms commonly used when reading about health statistics
3. Learn different ways health information can be collected, and the pros and cons of each
4. Become familiar with a variety of online sources for health statistics
5. Create a set of strategies to find specific health statistics



<https://grants.nih.gov/grants/guide/notice-files/NOT-LM-20-017.html>

Request for Information (RFI): Information and Data Resources Needed by the Health Services Research Community for Research and Practice.



Vision

A world in which evidence informs decisions for optimal health for all.



Mission

AcademyHealth improves health and health care for all by advancing evidence to inform policy and practice.

Vision

- **I. Impact**

Accelerate and amplify efforts to ensure that high quality, trustworthy data, valid measures and evidence are used for decisions in policy and practice.

- **II. Workforce**

Develop and sustain a diverse workforce to respond to the changing needs of stakeholders who need evidence to advance health and health care improvement.

- **III. Engagement**

Enhance our engagement with the individuals and organizations who use evidence to drive health improvement and health equity in the future.

- **IV. Innovation**

Embrace innovation, technology and other societal trends to advance and inform new and relevant evidence to achieve health improvement for all.

HEALTH SERVICES RESEARCH

HSR is the multidisciplinary field of scientific investigation that studies how social factors, financing systems, organizational structures and processes, health technologies, and personal behaviors affect access to health care, the quality and cost of health care, and ultimately our health and well-being.

National Academy of Medicine, 2018



NLM and AcademyHealth collaborate to host professional development activities.



The Back to School Webinar has been an annual tradition since 2015.



The HSRProj Research Competition for Students has been an annual tradition since 2017.



Presenters and Objectives

PRESENTERS



**Ernest Moy, M.D.,
M.P.H.**



Jodie Trafton, Ph.D.



**Suzanne Tamang,
Ph.D.**



Alyce Adams, Ph.D.





Learning Objectives:

- At the conclusion of this webinar, participants will be able to:
 - Describe ways big data can be applied to enhance public health and health services research
 - Define predictive modeling
 - Identify practical considerations in the implementation of predictive modeling



Introduction to data science tools and methods

Ernest Moy



TOP MACHINE LEARNING ALGORITHMS YOU SHOULD KNOW

- Linear Regression
- Logistic Regression
- Linear Discriminant Analysis
- Classification and Regression Trees
- Naive Bayes
- K-Nearest Neighbors (KNN)
- Learning Vector Quantization (LVQ)
- Support Vector Machines (SVM)
- Random Forest
- Boosting
- AdaBoost






Real World Predictive Analytics in Learning Health Systems

- Predictive Analytics: Use of current & past data to predict future outcomes.
- Real World
 - Model has to work reliably.
 - Data has to be processed to give answers in time to act.
 - Tool has to be acceptable and understandable by users.
- Learning Health System
 - Model improves health.
 - Model evolves, e.g., to reduce inequities.

■ Veterans are more likely than Non-Veterans to fill opioid prescriptions in recent years.



Source: Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey, 2014-2017.



Development of the predictive model and the randomized trial to test the application of the model

Jodie Trafton



Design of a predictive model

- Needs to align with its use case!!!
- Many design decisions will need to be made as you develop and optimize your model
- These should be informed by your intended use of the model
- Here, I will walk you through:
 - the genesis of our use case for the STORM predictive model,
 - how that informed design and development of the model,
 - and our implementation of the model into clinical practice.

In 2010: Clinical Practice Guidelines for Chronic Opioid Therapy and Substance Use Disorder



Guidelines available



Recommended effective
treatments and risk
mitigation strategies



Not consistently
implemented in practice

How could we facilitate guideline-based practice?

- Worked with guideline authors
 - Operationalized guideline concepts into codable data elements based on VHA medical record data
- Incorporated into a set of key guideline adherence metrics
- Built into computerized decision support that presented key risk factors and tracked patient tailored recommendations for care
- Pilot tested in primary care practice

The screenshot displays the 'ATHENA Opioid Therapy for Chronic Non-Cancer Pain' application. At the top, there is a header bar with navigation tabs: Summary, Assessment, Orders: Urinary Drug Screens/Meds/Consults, Education & Agreements, and Documentation. Below the header, a patient information field shows 'Patient name, SSN and date of birth'. A disclaimer states: 'Disclaimer: Complete clinical information may not be available to the Athena Opioid Therapy application herein displayed. Please use all information you have about the patient together with your clinical judgment to decide on the best therapy for this patient's chronic pain.' The main content area is titled 'Recommendations for Chronic Pain Management'. It includes a 'Cautions' section with a pink background listing 'COPD', 'Current or past drug-induced mental disorder', 'Depression', and 'Age >=65 years'. Below this is a table for 'Opioids' with columns for Drug, Daily Dose, Start, and End. The table lists 'hydrocodone/a...' with a daily dose of '20.0'. To the right of the table is a 'Treatment Checklist' with several items, each preceded by a checkbox: 'Conducted Pain Assessment', 'Ordered a Urine Drug Screen', 'Educated Patient to Call Ahead for Refills (7-10 days Before Running Out)', 'Had Patient Sign Pain Management Agreement', and 'Documented Pain Assessment, UDS, Patient Education, Pain Management Agreement'. On the far right, a sidebar titled 'Opioid Therapy Options' provides detailed guidance. It includes options like 'Increase dosage of short-acting opioid (hydrocodone/acetaminophen)' and 'Switch from hydrocodone/acetaminophen to morphine SA'. It also lists contraindications for hydrocodone/acetaminophen (Obstructive Pulmonary Disease, Drug Induced Mental Disorder, Depression) and morphine SA (short acting rx for >2 months). A suggested schedule for morphine SA is provided: First week 1 x 15 mg tab bid (30 mg/day), Second week 1 x 15 mg tab bid (45 mg/day), and Third week 2 x 15 mg tab bid (60 mg/day). Comments advise follow-up with the patient by phone at the end of 2-3 weeks to titrate to level necessary for adequate pain relief. Other options include 'Maintain current therapy' and 'Discontinue opioid therapy. Evaluate for opiate dependence. Click for taper schedule.' A warning section states 'Close monitoring of opioid therapy in this patient is necessary (click to see reasons)' and lists reasons: 'Opioids are respiratory depressants and should not be used in the presence of hypercapnia and hypoxia on arterial blood gas determination' and 'Opioids may worsen depression and should be used when benefits outweigh risks.' A clinical alert at the bottom states 'Slow initiation or titration schedules are recommended for elderly patients.'



Why develop a predictive model?

- Decision support was highly rated by clinicians, but....
 - Was only consistently adopted by clinicians who were already following guidelines at high rates
 - Simplified following guidelines, but risk mitigation was still time consuming to do
 - Clinicians wanted to know when they really needed to prioritize opioid-related risk mitigation
- Clinical Question:
 - Given that I don't have time to implement all risk mitigation with all patients, when should I prioritize these interventions over other clinical priorities?
 - Which patients are likely to suffer harm from not receiving full risk mitigation?



A second use case

- Meanwhile, we were starting a national Overdose Education and Naloxone Distribution (OEND) program
 - Set up protocols and clinician and patient trainings to facilitate overdose prevention, identification and rescue protocols
 - Providers wanted to know which patients needed to be prioritized to receive OEND
- Clinical Question:
 - Which patients with access to opioids are most likely to experience an accidental overdose or suicidal ideation/behavior?



Modeling Goal: Predicting what for whom?

- Develop a predictive model that estimates risk of overdose or suicide ideation/behavior among patients exposed to opioids
 - Modeled in two cohorts
 - Patients who received an opioid prescription
 - Patients with opioid use disorder
- Do we need separate models for suicide and overdose risk?
 - Modeled separately and together
 - Extremely similar. Combined for usability.



Modeling decision 1: Predictor Inclusion


- Initially considered all codable data elements defined with the guideline authors
- Found that nearly all risk mitigation strategies were positive predictors of risk
 - Selectively applied to higher risk patients in clinical practice
 - Removed these from model
 - Goal of model was to increase use of these interventions
 - Intervening would increase risk estimation
 - Confusing and discouraging to clinicians
- Included all patient factors
- Excluded clinical interventions except for prescription fills
 - Wanted to account for risk due to medications taken
 - Incorporated clinical interventions in decision support



Strong diagnostic and health care event risk factors for overdose or suicide-related events

Risk factor	Odds Ratio	Model Parameter
• Prior overdose or suicide-related event	23.1	2.62
• Detoxification treatment	18.5	.06
• Inpatient mental health treatment	16.6	1.0
• Sedative use disorder diagnosis	11.2	.23
• Stimulant use disorder diagnosis	8.1	.73
• Opioid use disorder diagnosis	8.0	.31
• Mixed substance use disorder	8.0	.33
• Cannabis use disorder	5.9	.27
• Bipolar disorder	5.8	.82
• Alcohol use disorder	5.3	.36
• Other mental health disorder	5.7	.73
• Major Depression	4.8	.61
• Emergency Department visit	3.4	.72
• Fall or accident	2.9	.44
• PTSD	2.6	.34
• Tobacco use disorder	2.2	.18
• AIDS	2.2	.20
• Liver Disease	2.2	.15
• Other neurological disorder	2.1	.18
• Electrolyte disorders	2.0	.19

MH/SUD and Non-Opioid Related Factors Have Higher Odds Ratios than Opioid-Related Factors in VHA Predictive Model




STORM Analysis: Oliva et. al. Psych. Services 2017



High Odds Ratios for Other Evidence-Based Sedating Pain Medications

Odds Ratios for Overdose/Suicide-Related Events





Modeling decision 2: What modeling strategy?

- Experimented with multiple modeling strategies using the same core dataset
 - Cohort 1: All patients with an opioid prescription in FY2010
 - Cohort 2: All patients seen for an opioid use disorder in FY2010
 - Predicting overdose and suicide through FY2011
- Findings:
 - Similar model performance with multiple modeling approaches
 - Good prediction for opioid therapy cohort.
 - Poor model performance for Opioid Use Disorder cohort
 - Whole cohort at high risk with no obvious predictors that substantially distinguished risk between patients
 - Final model included: Random effects for region and health care system, interaction terms to handle commonly co-occurring predictors (e.g. inpatient treatment and detoxification procedures)

Why implement the logistic regression model?

- Simplicity
 - Clinicians were typically familiar and comfortable with regression models
 - facilitated trust
 - Relatively easy to calculate nightly in our SQL-based data warehouse
- Included all clinically expected predictors
 - Clinicians expressed discomfort with excluding predictors
 - Wanted all of the factors they felt were clinically important searched for and considered in the model and decision support
- Performed as well as other models
 - Similar AUC
 - Similar risk enrichment in top cohorts

Model performance

Mean Predicted Risk Scores, Actual Overdose- or Suicide-Related Event Rates, and Sensitivity and Specificity for Varying Risk Cohorts.

Note. 23,790 total overdose or suicide-related events in FY2011 among 1,135,601 patients (2.1%).

Risk Cohorts (N subjects with the highest risk scores)	Mean Predicted Risk Score (range 0-100)	Actual overdose/ suicide-related event rate in FY2011	True Positive Sensitivity for this Cut Point	False Negative 1-Specificity for this Cut Point
1,000	57.9	53.7% (~1 in 2)	0.025	0.00041
10,000	38.1	36.2% (~1 in 3)	0.152	0.0057
100,000	11.8	11.9% (~1 in 10)	0.502	0.079
500,000	4.0	4.1% (~1 in 25)	0.850	0.432
1,000,000	2.3	2.3% (~1 in 50)	0.985	0.878



Did the model meet the clinical need?

Improved efficiency of identification of patients with adverse events over individual predictors or target populations

Risk approaches for VA patients prescribed opioids	Risk-model based (STORM top 20,000 patients)	MEDD > 200 mg	Opioid Use Disorder diagnosis	Co-prescribed sedative medication
Total number in VA in FY2010	20,000	19,496	20,871	185,477
Total number of opioid or suicide-related events in FY2011	5780	882	2779	4951
% of all opioid or suicide-related events in FY2011 (N=23,790)	24.3%	3.7%	11.7%	20.8%
% of risk cohort with an opioid or suicide-related event in FY2011	28.9%	4.5%	13.3%	2.7%
Minimum risk score in cohort	17.3%	0.3%	0.4%	0.1%
Median risk score in cohort	26.8%	2.5%	6.5%	1.3%
Maximum risk score in cohort	79.8%	78.2%	79.8%	79.8%

Comparison of Different Risk Approaches (Risk-Model Based [STORM] versus Individual Risk-Factor Based)




How did we use it?

- Used VA Corporate Data Warehouse and Business Intelligence platform
 - SQL database with nightly extracts of all 130 VA medical records
 - Access controls for report permissions based on staff medical record access
- Built decision support as a MS SSRS report
 - Set up nightly extraction of risk predictors
 - Estimated risk for all patients with active opioid prescriptions
 - Posted on reports designed for:
 - Facility/Team/Provider summary
 - Population Management
 - Patient look-up
 - Focus on encouraging and tracking risk mitigation
 - Patient stratification by modeled risk



STORM—Family of decision support tools to support safe care of patients exposed to opioids

Includes: Predictive analytics for risk stratification, flexible population management, summary information on risk mitigation implementation for targeting QI and education, recommendation and tracking of risk mitigation, and patient level care review.



STORM Patient Detail Report

Stratification Tool for Opioid Risk Mitigation

Data displayed has a 1-2 day lag from CPRS entry. This report is to be used along with the electronic medical record and direct discussion with the patient to help facilitate decision making. STORM predicts risk of overdose or suicide-related health care events or death. STORM should not be used for research, only for operational and quality improvement purposes. Warnings: Discontinuing opioids does not necessarily reduce your patients' risk and may actually increase their risk. Always discontinue opioids with caution and clinical support.

[Home](#) [About](#) [Definitions](#) [User Guide](#) [Contact Us](#) [Quick View Report](#) [SSN Look-Up](#) [Save/Share Current View](#)

Total Patients: 5


Patient Information	What factors contribute to my patient's risk?		How to better manage my patient's risk		How can I follow-up with this patient?		
	Relevant Diagnoses	Relevant Medications	Risk Mitigation Strategies	Non-pharmacological Pain Tx	Care Providers	Recent Appts	Upcoming Appts
ZZTESTPATIENT,BATMAN MACK Last Four: 2179 Age: 29 Gender: M Risk: Suicide or Overdose (1 yr)* Very High - Active Opioid Rx 6% <i>PRF - High Risk for Suicide: No</i> RISORD: Score: 43 Risk Class: 5 Active Station(s) ● (600) Long Beach, CA Chart Review Note	Mental Health Major Depressive Disorder Other MH Disorder Medical Chronic Pulmonary Dis Diabetes, Uncomplicated Hypertension Lymphoma Neurological disorders - Other Paralysis Peripheral Vascular Disease Sleep Apnea Adverse Event Related to falls	Non-VA MARIJUANA ● Dr Zivago Opioid MORPHINE Months in Treatment: 1 ● Dr Zivago ACETAMINOPHEN/HYDROCODONE Months in Treatment: 6 ● Dr Zivago Pain Medications (Sedating) DULOXETINE ● Dr Zivago PREGABALIN ● Dr Zivago TOPIRAMATE ● Dr Zivago Opioid Prescription History	Bowel Regimen <input checked="" type="checkbox"/> Data-based Opioid Risk Review <input type="checkbox"/> MEDD <= 90** <input checked="" type="checkbox"/> 45 Naloxone Kit <input type="checkbox"/> 3/30/2018 PDMP <input checked="" type="checkbox"/> 1/13/2020 State PDMP List Psychosocial Assessment <input checked="" type="checkbox"/> 11/7/2019 Psychosocial Tx <input checked="" type="checkbox"/> 1/23/2020 Suicide Safety Plan <input checked="" type="checkbox"/> 10/31/2019 Timely Follow-up (90 Days) <input checked="" type="checkbox"/> 1/27/2020 Timely UDS (1 Year) <input checked="" type="checkbox"/> 1/18/2020	Active Therapies <input checked="" type="checkbox"/> 1/23/18 CIH Therapies <input checked="" type="checkbox"/> 1/23/15 Chiropractic Care <input type="checkbox"/> Occupational Therapy <input checked="" type="checkbox"/> 1/23/17 Pain Clinic <input checked="" type="checkbox"/> 9/4/15 Physical Therapy <input checked="" type="checkbox"/> 1/23/19 Specialty Therapy <input checked="" type="checkbox"/> 1/23/18 Other Therapy <input checked="" type="checkbox"/> 7/9/13	Care Providers	Primary Care Appointment ● 4/16/2017 Primary Care/Medicine OtherRecent ● 1/27/2018 Telephone Case Management Specialty Pain ● 9/4/2017 Pain Clinic MH Appointment None	Primary Care Appointment None OtherRecent ● 1/30/2017 Spinal Cord Injury Specialty Pain None MH Appointment None

↑
Patient Information and Risk of Suicide/Overdose

↑
Contributing Risk Factors

↑
Risk Mitigation Strategies and Non-pharmacological pain treatments

↑
Care team & Follow-up





A randomized policy evaluation to test the application of the model

Jodie Trafton

Mandating Interdisciplinary Case Review for Patients estimated at “very high” risk

Turning predictive modeling-based decision support into a targeted prevention intervention.

Implemented at VHA's 141 Health Care Systems

2 randomized components:

- Timing of expansion of “very high” risk population
- Centralized oversight and Action planning

Department of Veterans Affairs
Veterans Health Administration
Washington, DC 20420

VHA NOTICE 2018-08
March 8, 2018

CONDUCT OF DATA-BASED CASE REVIEWS OF PATIENTS WITH OPIOID-RELATED RISK FACTORS

1. VHA is committed to enhancing the safe and efficacious care of Veterans who are exposed to opioid drugs. Deploying risk mitigation strategies or modifying treatment plans for patients at elevated risk of experiencing an adverse event related to an opioid prescription or opioid use disorder diagnosis can reduce the likelihood of these events and improve patient outcomes.

2. This VHA notice establishes policy on implementation of Opioid Safety Initiative (OSI) case reviews, and Title IX, Subtitle A, Section 911(a)(2) of the Comprehensive Addiction and Recovery Act (CARA). These case reviews must be documented in the medical record using a note title or titles that include the terms “Opioid Risk Review” and “Data-based”. These both require completion and documentation of case reviews of opioid-related risks, specifically for the following two groups of patients:

(a) Patients identified as being in the “Very High – Opioid Prescription” risk category for an overdose or suicide-related event by the Stratification Tool for Opioid Risk Mitigation (STORM); these patients must be included in the interdisciplinary OSI case reviews of patients with high risk opioid prescribing at each facility.

(b) Patients with new opioid prescribing, before initiating opioid therapy by the health care provider.

3. Detailed background, implementation instructions, and monitoring plans regarding this guidance are available at:

https://spsites.cdw.va.gov/sites/OMHO_PsychPharm/vti_bin/ReportServer?https://spsites.cdw.va.gov/sites/OMHO_PsychPharm/AnalyticsReports/STORM/Memo.rdl&rs:Command=Render&rs:Format=PDF

4. Staff from the Program Evaluation and Resource Center (PERC) within the Office of Mental Health and Suicide Prevention (OMHSP) will conduct a series of seminars that provide an overview of STORM and suggestions on how to use STORM for case review. The STORM implementation team will be available for technical assistance with the STORM dashboard or to assist with developing strategies and processes for case review.

5. Local facility leadership should facilitate implementation of case reviews in four additional ways:

(a) Designate a contact person or team of people for this initiative and notify the STORM implementation team at V21PALSTORMteam@va.gov of the name and contact information for each team member. We expect these contacts will typically comprise or include the current Opioid Safety Initiative Point of Contact (OSI POC; see

attached list). This contact person or team will receive information about updates and trainings on STORM and opioid risk mitigation and may be contacted for qualitative information about their local implementation.

(b) Ensure that staff on the Pain Management Teams, mandated in the 10N memorandum, Comprehensive Addiction and Recovery Act Requirements from Section 911(c) Pain Management Team Facility Report, dated May 22, 2017, found here https://vaww.va.gov/vhapublications/ViewPublication.asp?pub_ID=5915, or Opioid Safety Initiative review teams have interdisciplinary representation and adequate time dedicated to complete the case reviews and follow-up required in 2(a). **NOTE:** This is an internal VA Web site that is not available to the public.

(c) Ensure training and adequate encounter time for clinicians considering initiating opioid therapy to conduct reviews of opioid-related risk per 2(b).


(d) Require a Clinical Application Coordinator (CAC) at the facility to establish a local pre-defined progress note(s) including “Opioid Risk Review” and “Data-based” in the title.

6. Questions regarding this VHA notice should be directed to Dr. Friedhelm Sandbrink, Acting Director, National Pain Management Program, VHA, at Friedhelm.Sandbrink@va.gov or the STORM implementation team at V21PALSTORMteam@va.gov.

7. This VHA notice will be archived as of March 31, 2019. However, the information will remain in effect.

Carolyn M. Clancy, M.D.
Executive in Charge

DISTRIBUTION: Emailed to the VHA Publications Distribution List on April 16, 2018.



¹Partnered Evidence-Based Policy Resource Center

²Center for Health Equity Research and Promotion

Fig. 1 Design for clinical (PEPReC) and implementation evaluations (CHERP)



Outcomes Associated with Targeting Interdisciplinary Case Review to Patients Estimated at “Very High” Risk of Overdose or Suicide-Related Events

Stepped-wedge designed expansion of population characterized as “very high” risk

Patients with risk scores between 1% and 5%

											Step 1						Step 2						
Clinics 1-70																							
Clinics 71-140																							
Timeline (month)	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23

control

Patient enters the 1% to 5% risk range in a white facility-month cell

treatment

Patient enters the 1% to 5% risk range in a green facility-month cell

STORM trial was a 23-month, multi-center stepped wedge cluster randomized trial.

All 140 VA medical centers were included and received the intervention by the end of the study.

Each medical center entered the study on April 18, 2018, and randomly crossed over into the intervention conditions in two waves: study month 11 and month 17.

Participants

- Eligible participants were VA patients with an active prescription for opioids with a predictive risk of SAE in the top 1-5% of all patients, after the start of the trial.
- Patients with OUD and/or risk scores in the top 0-1% had previously received the intervention and were ineligible for the study analyses.

Comparing Control and Treatment Patients

- Predominantly white, male
- Average age is 58 at baseline
- Sample is evenly balanced between control and treatment conditions
- We also examined balance for 31 different comorbidities

	Control (n=41,816)	Treatment (n=22,967)	Standardized difference
Sex			
Male	85.6%	85.0%	0.02
Race			
White	69.9%	71.7%	0.04
Black	23.8%	21.9%	0.04
Other	6.32%	6.9%	0.00
Marital Status			
Married	41.1%	42.3%	0.03
Single/Never Married	14.8%	14.2%	0.02
Div/Sep/Widowed	43.7%	43.1%	0.01
N/A	0.4%	0.4%	0.01
Other			
Age (avg.)	58.4	59.1	0.05
Homeless	12.4%	10.4%	0.06



Outcomes of Interest

- The primary outcomes of interest were opioid-related serious adverse events (SAEs) and all-cause mortality within 127-days following the intervention.
- SAE's included:
 - Opioid overdose, sedative overdose, acetaminophen overdose, other drug overdose, motor vehicle accident, accidental falls, other accidents, and possible and confirmed suicide-related events.
 - A measure of 'any' SAE



Regression Models


- A patient-level logistic mixed model regression was used to estimate the impact of treatment on the likelihood of outcomes, controlling for time, facility and patient characteristics.
- A statistically significant estimate indicates the odds ratio of experiencing an opioid related SAE or all-cause mortality due to being included in the STORM “very high risk” cohort mandated for risk review.



Effect of being mandated to receive an interdisciplinary case review (patients in top 1-5%)

Impact of STORM Dashboard Inclusion on Risk of Serious Adverse Events and Mortality

Top 1-5% STORM dashboard patients had **23%** lower odds of all-cause mortality in the next 4 months when labeled “very high” risk and subject to mandate for interdisciplinary case review



*Effect of being included as “very high” risk due to mandate expansion, regardless of whether the mandated patient received a case review



Implications


- The odds of all-cause mortality for STORM dashboard patients relative to control patients was **0.773** (95% CI: 0.639, 0.937).
- This translates to approximately 180 lives saved in the first 4 months after identification in the 1-5% risk group.
- Ascertainment bias is a potential concern in detecting SAE's. Mortality is a more reliably captured outcome.
- Mechanism may be due to increased probability of receiving a case review.
- The odds of receiving a case review for STORM dashboard patients relative to control patients was **6.263** (95% CI: 3.946, 8.580).



Outcomes associated with getting an interdisciplinary case review among patients in top 1%

Associations between case review and SAE/mortality in the 0-1% risk group

Among the top 1% risk patients, when patients' case review status was “completed” (from month they were case reviewed plus 12 months) their **risk of Any SAE or death were reduced**



*Effect of getting a review among those always mandated to receive one



**Current work looking at
algorithmic racial and gender bias
in the model that may guide future refinement**
Suzanne Tamang



Algorithmic Bias : *What is it?*



Should we be concerned?

Why should we be concerned?


■ Receiver Operating Characteristic Curve

The ROC curve is created by plotting the **true positive rate (TPR)** against the **false positive rate (FPR)** at various threshold settings.

The true-positive rate is also known as ***sensitivity, recall or probability of detection*** in machine learning. The false-positive rate is also known as ***probability of false alarm*** and can be calculated as $(1 - \text{specificity})$. The ROC curve is the sensitivity or recall as a function of **fall-out**.

ROC Curve and AU-ROC: Race x Ethnicity

2016-2017







In Sample

Out Sample

Hispanic

Non-Hispanic



■ Precision Recall Curve

The Precision Recall curves are created by plotting the Precision, also known as the *positive predictive value* and Recall, the *true-positive rate*. Recall is more commonly called *sensitivity* in medicine and is the probability the model will predict all positive cases for the outcome.



In contrast to the ROC curves and ROC-AUC statistics, the Precision-Recall Curve and the PR-AUC performance metric provide *more information on prediction scenarios that involve rare binary events*.

Race X Sex



Male

Female

In Sample



Out Sample



■ False Negative Parity

The *false-negative rate* represents the percentage of true positives missed by the prediction model.

False-negative parity describes the closeness of the false positive rate (false positives/true positives) across different subgroups of interest. It is commonly reported in algorithmic bias analyses.




PR Curve and AU-PRC: Race x Age

Under 50




50-65

Over 65

In Sample



Out Sample




Calibration is defined as the following property:

“If we assign some group a risk of x , the actual outcome incidence rate should also be x ”


For example, if we assign a group of people a risk of 10%, the actual overdose/suicide-related incidence rate should also be 10%.

■ Calibration: Race

In Sample




Out Sample



SAE Trends X Race during modeling period

Age-adjusted drug poisoning rates

from: <https://www.cdc.gov/nchs/data-visualization/drug-poisoning-mortality/>



Sharp jump in drug poisoning rates between 2015 and 2018

Increase varied by race/ethnicity

Large relative increase in drug poisoning rates in Black population:

Year	Black	White
2015	12.2	21.1
2017	20.6	27.5

Emphasizes the need for on-going calibration of predictive models, particularly when population risk is evolving rapidly.



Discussion

Alyce Adams, Jodie Trafton, Suzanne Tamang, &
Ernest Moy





References

- Buscaglia AC, Paik MC, Lewis E, **Trafton JA**, VA Opioid Metric Development Team. (2015) Baseline Variation in Use of VA/DOD Clinical Practice Guideline Recommended Opioid Prescribing Practices across VA Health Care Systems. *Clinical Journal of Pain* 31(9): 803-812.
- **Trafton JA**, Martins SB, Michel MC, Wang D, Tu SW, Clark DJ, Elliot J, Vucic B, Balt S, Clark ME, Sintek CD, Rosenberg J, Daniels D and Goldstein MK. (2010) Designing a computerized decision support system to match consensus guidelines for opioid therapy for chronic pain. *Implementation Science* 5:26.
- Midboe AM, Lewis ET, Paik MC, Gallagher RM, Rosenberg JM, Goodman F, Kerns RD, Becker WC, **Trafton JA**. (2012) Measurement of Adherence to Clinical Practice Guidelines for Opioid Therapy for Chronic Pain. *Translational Behavioral Medicine*. 2:57-64.
- Im JJ, Shachter RD, Oliva EM, Hernandez PT, Paik MC, **Trafton JA**. (2015) Association of Care Practices with Suicide Attempts in US Veterans Prescribed Opioid Medications for Chronic Pain Management. *Journal of General Internal Medicine* 30(7):979-91



Thank you

*Please take a moment to fill out the
brief evaluation available on the webinar page*



AcademyHealth